clinical trial · NCT04522817
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
Covid-19CLBS119
brief summary
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.
started
Oct 5, 2020
primary completion
May 1, 2021
completion
May 1, 2021
last updated
Oct 9, 2024
detailed description
This open-label clinical trial will explore the safety and potential efficacy of peripheral blood derived autologous CD34+ cells for the repair of COVID-19 induced pulmonary damage in adults. Eligible subjects will receive a single administration of CLBS119.
official title
CLBS119 (Autologous Peripheral Blood Derived CD34+ Cells) for Repair of COVID-19 Induced Pulmonary Damage
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol